drugset / Trial / NCT01179191

Conversion to Embeda With Rescue Trial

NCT01179191

Phase 4 Terminated 684 enrolled Pfizer
NaSingle-groupOpen-labelSupportive care

Summary

The purpose of the research study is to find out if opioid dependent chronic pain patients who are judged by their physician to be eligible to change their current opioid medicine and to participate in this study can be successfully adjusted to a stable dose of EMBEDA (morphine sulfate and naltrexone hydrochloride). The study will also assess each patient's risk for prescription opioid abuse, misuse and diversion.

Timeline

Start
2010-08
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Morphine Other / unclassified 20 mg Oral
Subject Morphine Other / unclassified 100 mg Oral
Subject Naltrexone Small molecule 0.8 mg Oral
Subject Naltrexone Small molecule 4 mg Oral

Indications

No indication recorded.